Climb Bio Announces CLYM116 Preclinical Data Highlighting Potential for Best-In-Class Therapeutic for IgAN

About this update from Climb Bio, Inc.

[{"type":"image","alt":"Climb Bio, Inc.","displaySize":"","headline":null,"caption":"Climb Bio, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/96b5fbbb4dd8bc4bbccc298a6909629c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/upR1wQHp9TCZxvAhULaG8g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/96b5fbbb4dd8bc4bbccc298a6909629c","width":300,"height":300}},"lazy":false},{"type":"text","content":"New preclinical data demonstrate deeper IgA reduction and a longer half-life compared to first-generation anti-APRIL monoclonal antibody","length":136,"tagName":"p"},{"type":"text","content":"CLYM116 Phase 1 trial initiation expected in Q4 2025, with initial biomarker and dosing interval data anticipated mid-year 2026","length":127,"tagName":"p"},{"type":"text","content":"Company to host R&D Spotlight Webcast today, September 29, 2025","length":67,"tagName":"p"},{"type":"text","content":"WELLESLEY HILLS, Mass., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced results from a completed nonhuman primate (NHP) study comparing CLYM116 to sibeprenlimab, a first-generation anti-APRIL monoclonal antibody. The company is hosting a virtual investor event focused on CLYM116 today, Monday, September 29, 2025, at 8:00 a.m. ET. Climb Bio’s management team will be joined by leading nephrologist Craig E. Gordon, MD, MS, who has over 20 years of experience treating patients with IgA nephropathy (IgAN) and was a co-director of the Evidence Review Team for the recently issued 2025 KDIGO Clinical Practice Guideline for IgAN.","length":766,"tagName":"p"},{"type":"text","content":"“We are highly encouraged by the differentiated profile observed with CLYM116, as highlighted in our newly shared nonhuman primate data,” said Aoife Brennan, President and CEO of Climb Bio. “CLYM116 is the only known ‘sweeper’ anti-APRIL monoclonal antibody in development, which we believe could provide a compelling clinical profile in IgAN. In this head-to-head preclinical study, our data have shown improvements in pharmacokinetic and pharmacodynamic measures – namely a longer half-life and deeper and more durable IgA redu...

More updates from Climb Bio, Inc.